Natural immunity boosters: Clinical trial reports

Background 

Neurocognitive disorder is a disorder which is characterized by decrease in the intellectual function due to some disease of the brain caused due to cerebrovascular disease, Alzheimer’s disease, infections, adverse drug reactions or trauma. The COVID-19 infection has caused various viral-related mental and physical health problems which in due course has impacted the psychology of the whole society in large. The stress related to COVID-19 pandemic affects the cytokinine system and cholinergic pathways which caused depression and poor cognitive performance. To, help maintain the normal health and good immunity, health drinks have become a part of daily life. Hence, a study was carried out to study the protective effect of Mulmina® against neurocognitive disorders and justify the effectiveness of Mulmina®.¹

Study design ²

• The study was designed to determine the effectiveness of Mulmina against neurocognitive disorders induced by chemotherapy.
• Chemotherapy was induced in male swiss albino mice weighing 20-30 g by treating with cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
• For 21 days, the animal were also treated with Mulmina and compared with the effects of standard drug donepezil.

Method ²:

• The parameters that were evaluated included
• Behavioural parameters: Open field test (OFT) for locomotor activity; Morris Water Maze (MWM) for learning and memory.  Estimation of antioxidant parameters in brain homogenate: Catalase, lipid peroxidation (LPO).
• Estimation of hematological parameters: Total and differential WBC, RBC, platelet count and hemoglobin content.
• Parameters to understand the mechanism of Mulmina® Mango: Brain IL-6, Brain TNF-α, brain-derived neurotrophic factor (BDNF).

Results ²

The study showed that  when the mice was treated with both doses of Mulmina® in the Morris Water Maze test, a significant improvement in the spatial memory of animals was observed., which indicate that Mulmina® was effective in protecting  the hippocampus from the inflammation-induced damage

The OFT concluded that all the animals were equal in cognitive abilities before the start of the water maze test.

When compared to CMF, a lower dose of Mulmina® i.e. 40 mL/kg/day (24±4.0), higher dose i.e. 80 mL/kg/day (16±3.7) and donepezil (16±6.3) showed significant escape latency (ELT) at (p ≤0.05).

A Significant difference (p ≤0.05) was observed in terms of retention time (RT) with the high dose of Mulmina® (20±3.3), when compared with CMF.

A Significant reduction was seen in the latency to first line crossing (FLC) when compared to CMF in both lower (7.8±1.9) as well as higher dose of Mulmina® (2.9±0.46) and donepezil (5.9±1.2)  when compared to CMF (17±2.3).

Discussion ^2,3

Significant protective effects were observed on hippocampus from the inflammation –induced damage. Increase in the total leukocyte count and differential leukocyte count indicates inflammatory reaction within the body. Levels of pro-inflammatory cytokinines such as IL-6 and BDNF were restored with Mulmina®. Anti-oxidant property was evident from the deceased levels of LPO and also no adverse effects on locomotor activity and hematological parameters was observed after treating with Mulmina®

Conclusion

The above studies show that Mulmina® exhibited the protective effect of Mulmina against neurocognitive disorders and may be helpful in restoring the stress generated due to the COVID-19 Pandemic and lead normal and healthy life.

References:

1. Mukaetova-Ladinska EB, Kronenberg G, Raha-Chowdhury R. COVID-19 and neurocognitive disorders. Curr Opin Psychiatry. 2021;34(2):149-56.
2. Mulmina, Scientific updates,Update-1, 1-64.